All of the following drugs are FDA approved for the treatment of predominantly classic subfoveal CNV in patients with neovascular AMD except for which one?

Correct Answer: Bevacizumab (Avastin)

Bevacizumab given intravitreally is a common off-label treatment for all CNV lesion subtypes in any fundus location in neovascular AMD, but is not specifically FDA approved for this indication.